R&D capability and alliance formation in the pharmaceutical industry in India

G D Sandhya and S Visalakshi

Science and Public Policy, 2000, vol. 27, issue 2, 109-121

Abstract: This paper looks into the nature of alliances in the Indian pharmaceutical industry, which is developing fast internally and externally. A sample of 33 companies (significant in terms of size and R&D activity) included pharmaceutical firms using chemical-based methods of production, diversified firms based on chemical methods and biotechnology, and those which are doing biotechnology exclusively. The majority of linkages in the pharmaceutical industry are through sponsored research and alliances with universities, which is quite common in the early stages of innovation. In India, linked companies have relatively higher R&D intensity, work in more risky R&D propositions, and more basic serious R&D in biotechnology and related areas. The Indian companies use the linkages to take care of their skill deficiencies and facilities to take up R&D in new areas and also to upgrade their skills. Companies in advanced countries use alliances to complement their capabilities and to reduce risks and costs. Copyright , Beech Tree Publishing.

Date: 2000
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.3152/147154300781782101 (application/pdf)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:scippl:v:27:y:2000:i:2:p:109-121

Access Statistics for this article

Science and Public Policy is currently edited by Nicoletta Corrocher, Jeong-Dong Lee, Mireille Matt and Nicholas Vonortas

More articles in Science and Public Policy from Oxford University Press
Bibliographic data for series maintained by Oxford University Press ().